Semax (10mg)

Semax is a synthetic heptapeptide based on ACTH(4-7) (the fragment Met-Glu-His-Phe from adrenocorticotropic hormone) with an added Pro-Gly-Pro C-terminal extension for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside selank, semax is approved in Russia as a nootropic and neuroprotective medication. Semax does not activate the melanocortin receptors associated with full-length ACTH and does not affect cortisol or adrenal function. Instead, it influences brain function through modulation of neurotrophic factor expression. Research has shown semax significantly upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, as well as NGF (nerve growth factor) in the hippocampus and cortex. These neurotrophins are critical for neuronal survival, synaptic plasticity, and learning. Semax also modulates monoaminergic neurotransmission. It influences dopaminergic and serotonergic systems in the brain, which may contribute to its cognitive-enhancing and antidepressant-like effects observed in behavioral studies. In stroke research, semax has shown neuroprotective effects when administered during the acute phase of cerebral ischemia, reducing infarct volume and improving functional outcomes in animal models.

Semax is a synthetic heptapeptide based on ACTH(4-7) (the fragment Met-Glu-His-Phe from adrenocorticotropic hormone) with an added Pro-Gly-Pro C-terminal extension for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside selank, semax is approved in Russia as a nootropic and neuroprotective medication. Semax does not activate the melanocortin receptors associated with full-length ACTH and does not affect cortisol or adrenal function. Instead, it influences brain function through modulation of neurotrophic factor expression. Research has shown semax significantly upregulates BDNF (brain-derived neurotrophic factor) and its receptor TrkB, as well as NGF (nerve growth factor) in the hippocampus and cortex. These neurotrophins are critical for neuronal survival, synaptic plasticity, and learning. Semax also modulates monoaminergic neurotransmission. It influences dopaminergic and serotonergic systems in the brain, which may contribute to its cognitive-enhancing and antidepressant-like effects observed in behavioral studies. In stroke research, semax has shown neuroprotective effects when administered during the acute phase of cerebral ischemia, reducing infarct volume and improving functional outcomes in animal models.

Russian clinical protocols use intranasal doses of 250-500 mcg per day (typically 3 drops of 0.1% solution per nostril). Animal neuroprotection studies use 50-150 mcg/kg. Stroke studies used 12-18 mcg/kg/day intranasally.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.